“We have several important catalysts on the horizon during the next 12 months for our key programs,” said Carmine Stengone, CEO, Contineum (CTNM) Therapeutics. “First, we expect to report topline data from our PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) before the end of the year. We’re also on the cusp of initiating a comprehensive global Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF). Finally, we anticipate our PIPE-791 Phase 1b chronic pain trial will read out topline data in the first half of 2026.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Buy Rating for Contineum Therapeutics Driven by Strategic Positioning and Enhanced Efficacy in IPF Market
- Leerink bullish on Contineum, initiates with an Outperform
- Contineum initiated with an Outperform at Leerink
- Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results
- Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge